Cited 16 times in
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.